CANTON, Mass., May 4 /PRNewswire-FirstCall/ -- Avitar, Inc. (OTC Bulletin Board: - ) -- Avitar, Inc., developer of the first on-site oral fluid-based screen for drugs of abuse, today announced the results of a client-conducted month long field study comparing on-site oral fluid-based drug testing technology to traditional urinalysis.
A client spokesperson, Director of Risk Management & Human Resources for a mid-sized construction firm, explained the reasoning for the field test; "While the benefits of oral fluid-based drug screening were clear to us: instant results, no risk of sample adulteration, more efficient hiring practices and a better overall return on our investment in drug testing, we felt obligated to technically compare the performance of oral fluid versus urinalysis." The spokesperson continued, "We were impressed with the results of the study and feel very comfortable that our drug testing program will more effectively identify those employees who are using drugs. As a corporation we make every effort to take advantage of any new technology that contributes to the safety of our employees and provides better overall value to our customers."
Peter Phildius, CEO and Chairman of Avitar commented, "Our client's objective comparison between oral fluid-based drug testing and traditional urinalysis provides yet another example of the effectiveness of Avitar's technology. Phildius also noted, "The advantages of oral fluid testing communicated by our client also enable corporations to efficiently deploy random testing, proven to be the most effective tool available for eliminating on-the-job drug abuse."
Avitar, Inc. develops, manufactures and markets innovative and proprietary products. Their field includes the oral fluid diagnostic market, the disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Avitar manufactures ORALscreen®, the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, as well as HYDRASORB®, an absorbent topical dressing for moderate to heavy exudating wounds. Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy. For more information, see Avitar's website at https://avitarinc.com.
Safe Harbor Statement. This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.
VP of Marketing
Avitar Technologies, Inc.